Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/19/2025

Streptococcus constellatus Infection Management

Introduction to Streptococcus constellatus

  • S. constellatus belongs to the Streptococcus anginosus group, which can cause abscesses and serious infections, according to the European Heart Journal 2
  • The American Academy of Otolaryngology-Head and Neck Surgery recommends against using Bactrim (trimethoprim-sulfamethoxazole) as first-line therapy for Streptococcus constellatus infections due to inadequate coverage and potential resistance 1

Antibiotic Selection for S. constellatus Infections

  • Macrolide antibiotics and trimethoprim-sulfamethoxazole are not recommended for streptococcal infections due to high resistance rates, as stated by the American Academy of Otolaryngology-Head and Neck Surgery 1
  • Trimethoprim-sulfamethoxazole shows resistance rates of up to 50% against Streptococcus pneumoniae, raising concerns for other streptococcal species, according to the American Academy of Otolaryngology-Head and Neck Surgery 1
  • For patients with penicillin allergy, the American Academy of Otolaryngology-Head and Neck Surgery recommends respiratory fluoroquinolones (levofloxacin or moxifloxacin) as alternative therapy 1

Clinical Considerations for S. constellatus Infections

  • S. constellatus often causes abscess formation in various body sites, as reported in the European Heart Journal 2
  • Incision and drainage is the primary treatment for abscesses, with antibiotics as adjunctive therapy, according to Clinical Infectious Diseases 3, 4, 5
  • Duration of therapy should typically be 7-14 days for skin and soft tissue infections, but may need to be longer for deep-seated infections, as stated in Clinical Infectious Diseases 3, 4

Special Considerations for S. constellatus Infections

  • When S. constellatus is part of a mixed infection with MRSA, clindamycin alone or linezolid alone would provide adequate coverage for both organisms, according to Clinical Infectious Diseases 3, 4, 6
  • For mixed infections with gram-negative organisms, broader coverage may be needed initially, as reported in Clinical Infectious Diseases 5